Trial Profile

Effect of eribulin in patients with metastatic breast cancer on circulating TGFβ and TNFα: The TRANSERI project

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 21 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary)
Indications Advanced breast cancer
Focus Pharmacodynamics; Therapeutic Use
Acronyms The TRANSERI project; TRANSERI

Most Recent Events

05 Jun 2018 Results (n=24) investigating the interference among E and TGF-beta and TNF-alfa levels in pts and the correlation with the outcome and the metastatic spread presented at the 54th Annual Meeting of the American Society of Clinical Oncology
16 Jan 2018 New trial record
09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com